pregnant women with gestational diabetes mellitus magnesium oxide, magnesium supplementation, gestational diabetes mellitus
Conditions
Interventions
Oral magnesium oxide tablet/capsule administered for glycemic control.,Inactive placebo capsule identical in appearance and packaging to the magnesium oxide supplement to maintain blinding.
Experimental Dietary Supplement,Placebo Comparator Dietary Supplement
Magnesium oxide,Placebo
Sponsors
Department of Medical Services, Ministry of Public Health
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Singleton pregnancy 2. Receiving antenatal care (ANC) at Rajavithi Hospital 3. No obstetric complications 4. No medical conditions, including: Pre-gestational diabetes mellitus, Chronic hypertension, Chronic kidney disease, Autoimmune diseases (e.g., SLE), Hypothyroidism or hyperthyroidism 5. No history of hypothyroidism or hyperthyroidism 6. No history of hypersensitivity or allergic reaction to oral magnesium oxide supplement 7. No history of starch or gluten allergy 8. No history of previous cesarean section (C-section) 9. No history of stillbirth (intrauterine fetal death) 10. No history of hypertensive disorders of pregnancy 11. No history of preterm birth in a prior pregnancy 12. No history of shoulder dystocia in a prior pregnancy 13. Intending to deliver at Rajavithi Hospital. 14. Good command of the Thai language 15. Willing to participate in the study and provide informed consent
Exclusion criteria
Exclusion criteria: 1. History of magnesium supplement use within the 3 months prior to study enrollment 2. Laboratory results showing: HbA1C>= 6.5%, Cr > 0.8 mg/dL, serum magnesium < 1.8mg/dL or > 2.2 mg/dL 3. Presence of gestational hypertension 4. Presence of fetal chromosomal abnormality 5. Second-trimester ultrasound showing fetal abnormalities 6. History of using Milk of Magnesia (MOM) or Quinolone antibiotics (e.g., Ciprofloxacin, Levofloxacin) during the current pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| fasting blood sugar levels in pregnant women with gestational diabetes mellitus gestation age 35-37 weeks mean fasting blood sugar | — |
Secondary
| Measure | Time frame |
|---|---|
| Obstetric outcomes following oral magnesium oxide supplementation for glycemic control in pregnant women with gestational diabetes mellitus during pregnancy incidence of pregnancy induced hypertention, preterm birth, cesarean section, shoulder dystocia,Neonatal outcomes following oral magnesium oxide supplementation for glycemic control in pregnant women with gestational diabetes mellitus delivery incidence of stillbirth, Apgar score at 5 and 10 min, birth weight | — |
Countries
Thailand
Contacts
Public ContactPetnarmnueng Prommoon
Rajavithi Hospital, 2 Phaya Thai Road, Thung Phayathai, Ratchathewi, Bankok, 10400, Thailand
Outcome results
None listed